ACUTE MYELOID LEUKEMIA SIGNS/SYMPTOMS, CLASSIFICATION AND TREATMENT OPTIONS

ACUTE MYELOID LEUKEMIA SIGNS/SYMPTOMS, CLASSIFICATION AND TREATMENT OPTIONS

Library of Congress Cataloging-in-Publication Data

CONTENTS

PREFACE

Chapter 1 CLINICAL PRESENTATION OF ACUTE MYELOID LEUKEMIA

ABSTRACT

INTRODUCTION

INCIDENCE AND PATIENT CHARACTERISTICS

SYMPTOMS

ORGAN INVOLVEMENT

Skin

Ocular

Oral

Central Nervous System

Cardiovascular

Pulmonary

Gastrointestinal

Lymphoreticular

Musculoskeletal

LABORATORY FINDINGS

Complete Blood Counts

Coagulation Studies

Electrolytes

Leukocyte Larceny

CLINICAL SYNDROMES ASSOCIATED WITH AML

Leukostasis

Disseminated Intravascular Coagulation

Tumor Lysis Syndrome

Infection

Extramedullary Disease

CONCLUSION

REFERENCES

Chapter 2 PROGNOSIS OF CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA

ABSTRACT

INTRODUCTION

Subtypes of CBF AML

Clinical Prognostic Factors

Molecular Prognostic Factors

Cytogenetic Factors

Minimal Residual Disease

Other Factors

CONCLUSION AND FUTURE PERSPECTIVES

ACKNOWLEDGMENTS

REFERENCES

Chapter 3 PHILADELPHIA CHROMOSOME-POSITIVE ACUTE MYELOID LEUKEMIA

ABSTRACT

INTRODUCTION

Differentiating from Blast Phase Chronic Myeloid Leukemia

ClinicopathologicFeatures

Management

Role of Chemotherapy

Role of Tyrosine Kinase Inhibitors

Allogeneic Stem Cell Transplantation

Presence of Additional Abnormalities

CONCLUSION

CONFLICT OF INTEREST

ACKNOWLEDGMENT

REFERENCES

Chapter 4 THERAPY OF OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA

ABSTRACT

INTRODUCTION

PROGNOSTIC FACTORS

Patient-Related Prognostic Factors

Age

Performance Status

Comorbidities

Other Patient-Related Prognostic Factors

Disease-Related Prognostic Factors

WBC Count

Cytogenetics

Molecular Genetics

Mutations

Overexpression

Multidrug Resistance

Secondary AML

Other Disease Related Prognostic Factors

Response-Related Prognostic Factors

TREATMENT

Intensive Induction Chemotherapy

The Role of Cytarabine

The Role of Anthracycline

The Role of Other Cytotoxic Agents

The Role of Gemtuzumab Ozogamicin

The Role of Multidrug Resistance Modulators

The Role of Growth Factors

Non-Intensive Induction Chemotherapy

The Role of BSC

The Role of Low Dose Cytarabine (LDAC)

The Role of Clofarabine

The Role of Hypomethylating Agents

Azacitidine

Decitabine

Postremission Chemotherapy

CONCLUSION

REFERENCES

INDEX